home / openregs / federal_register

federal_register: 2019-27524

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2019-27524 Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Draft Guidance for Industry; Availability Notice The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products." This guidance complements and expands on the 1998 guidance entitled "Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products" (the 1998 guidance). Although FDA's evidentiary standard for effectiveness has not changed since 1998, the evolution of drug development and science has led to changes in the types of drug development programs submitted to the Agency. Specifically, there are more programs studying serious diseases lacking effective treatment, more programs in rare diseases, and more programs for therapies targeted at disease subsets. There is a need for more Agency guidance on the flexibility in the amount and type of evidence needed to meet the substantial evidence standard in these circumstances. 2019-12-20 2019 12 https://www.federalregister.gov/documents/2019/12/20/2019-27524/demonstrating-substantial-evidence-of-effectiveness-for-human-drug-and-biological-products-draft https://www.govinfo.gov/content/pkg/FR-2019-12-20/pdf/2019-27524.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products." This guidance complements and...

Links from other tables

  • 2 rows from document_number in federal_register_agencies
  • 1 row from fr_document_number in fr_regs_crossref
Powered by Datasette · Queries took 1.697ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API